Grant of Options and PDMR Dealing

Arecor Appoints Interim Chief Financial Officer

Interim Results for six months ended 30 June 2024

Notice of Results

Arecor presents positive AT278 data at EASD

Holding(s) in Company

Holding(s) in Company

Holding(s) in Company

Result of General Meeting and Total Voting Rights

Posting of Circular and General Meeting

Result of WRAP Retail Offer

WRAP Retail Offer to raise up to £1 million

Proposed Placing and Subscription

Result of AGM

Trading and Funding Update

Posting of 2023 Annual Report and Notice of AGM

Grant of Options and PDMR Dealing

Arecor to host company and KOL webinar today

Final results for 2023

Notice of Results

Arecor and Medtronic Diabetes collaboration

Publication of Full Year Financial Results delayed

Notice of results

BOARD CHANGE

Arecor and TRx Biosciences research collaboration

Arecor announces launch of Ogluo® in Netherlands

Year End Trading Update

Arecor announces update on INBRX-101

Arecor granted key European patent

Expansion of specialty hospital collaboration

Appointment of SVP for Tetris Pharma Ltd

Agreement with global medical products company

Arecor Continues Collaboration with Lilly

Product with Arestat technology launched in Europe

Inhibrx milestone triggers payment to Arecor

Exercise of rollover options & Total Voting Rights

Progress of Phase I clinical study of AT278

Interim Results for six months ended 30 June 2023

Arecor: positive Hikma FDA pre-IND meeting

Collaboration With Top 10 Global Pharma

Notice of Interim Results

Arecor Business Update

Additional Agreement with Leading Biopharma

Arecor granted key patents in Europe and China

Exercise of rollover options & Total Voting Rights

Result of AGM

AGM Statement

Director/PDMR Shareholding

ARECOR 2022 ANNUAL REPORT AND NOTICE OF AGM